These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 28039274)

  • 21. Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients.
    Abdulla A; Rogouti O; Hunfeld NGM; Endeman H; Dijkstra A; van Gelder T; Muller AE; de Winter BCM; Koch BCP
    Eur J Clin Pharmacol; 2020 Jul; 76(7):957-967. PubMed ID: 32307575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Temocillin dosing in haemodialysis patients based on population pharmacokinetics of total and unbound concentrations and Monte Carlo simulations.
    Miranda Bastos AC; Vandecasteele SJ; Spinewine A; Tulkens PM; Van Bambeke F
    J Antimicrob Chemother; 2018 Jun; 73(6):1630-1638. PubMed ID: 29579214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population Pharmacokinetics of Doripenem in Pediatric Patients and Monte-Carlo Pharmacokinetic-Pharmacodynamic Simulations for Dosing Regimen Assessment.
    Matsuo Y; Ishibashi T; Matsumoto S; Katsube T; Wajima T
    J Pharm Sci; 2019 Sep; 108(9):3099-3105. PubMed ID: 30974120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations.
    Conil JM; Georges B; Ruiz S; Rival T; Seguin T; Cougot P; Fourcade O; Pharmd GH; Saivin S
    Br J Clin Pharmacol; 2011 Jan; 71(1):61-71. PubMed ID: 21143502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population Pharmacokinetics and Pharmacodynamics of Doripenem in Obese, Hospitalized Patients.
    Chung EK; Fleming MR; Cheatham SC; Kays MB
    Ann Pharmacother; 2017 Mar; 51(3):209-218. PubMed ID: 28168884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients.
    Martial LC; Ter Heine R; Schouten JA; Hunfeld NG; van Leeuwen HJ; Verweij PE; de Lange DW; Pickkers P; Brüggemann RJ
    Clin Pharmacokinet; 2017 Oct; 56(10):1197-1206. PubMed ID: 28144840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population Pharmacokinetics and Dosing Optimization of Amoxicillin in Neonates and Young Infants.
    Tang BH; Wu YE; Kou C; Qi YJ; Qi H; Xu HY; Leroux S; Huang X; Zhou Y; Zheng Y; Jacqz-Aigrain E; Shen AD; Zhao W
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae.
    Noreddin AM; Hoban DJ; Zhanel GG
    Int J Antimicrob Agents; 2005 Aug; 26(2):120-5. PubMed ID: 16046101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of rheumatic fever prophylaxis regimens.
    Thamlikitkul V; Kobwanthanakun S; Pruksachatvuthi S; Lertluknithi R
    J Int Med Res; 1992 Feb; 20(1):20-6. PubMed ID: 1568517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients.
    Tietjen AK; Kroemer N; Cattaneo D; Baldelli S; Wicha SG
    Br J Clin Pharmacol; 2022 Feb; 88(4):1835-1844. PubMed ID: 34622478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physiologically Based Pharmacokinetic Model for Predicting Omadacycline Pharmacokinetics and Pharmacodynamics in Healthy and Hepatic Impairment Populations.
    Zhang A; Sun Y; Zuo M; Wei H; Chen J; Zhao M; Yang W; Zhu L
    Clin Ther; 2024 Aug; 46(8):629-635. PubMed ID: 39069431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Key Components of Intensified Ceftaroline Dosing on Pharmacokinetic/Pharmacodynamic Target Attainment.
    Minichmayr IK; Wicha SG; Matzneller P; Kloft C; Zeitlinger M
    Clin Pharmacokinet; 2024 Jan; 63(1):121-131. PubMed ID: 38007714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concentration of roxithromycin in the lesions of acne vulgaris.
    Akamatsu H; Horio T
    J Int Med Res; 2001; 29(6):537-40. PubMed ID: 11803739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.
    Bhavnani SM; Trang M; Griffith DC; Lomovskaya O; Hammel JP; Loutit JS; Cammarata SK; Dudley MN; Ambrose PG; Rubino CM
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0213021. PubMed ID: 36374023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical evaluation of roxithromycin 300 mg once daily as an alternative to 150 mg twice daily.
    Pechère JC
    Diagn Microbiol Infect Dis; 1992; 15(4 Suppl):111S-117S. PubMed ID: 1617922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Defining optimal dosing of ciprofloxacin in patients with septic shock.
    Roberts JA; Alobaid AS; Wallis SC; Perner A; Lipman J; Sjövall F
    J Antimicrob Chemother; 2019 Jun; 74(6):1662-1669. PubMed ID: 30809648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Pharmacokinetics and Tissue Distribution Kinetics of Roxithromycin and Expression of CYP 3A1 between Pregnant Mice and Foetuses.
    Qin Y; Xu W; Mo L; Li X; Ge B; Xiong J; Gao L; Xu P; Xue M
    Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):146-151. PubMed ID: 27611991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.
    Zhang J; Xu JF; Liu YB; Xiao ZK; Huang JA; Si B; Sun SH; Xia QM; Wu XJ; Cao GY; Shi YG; Zhang YY
    J Infect Chemother; 2009 Oct; 15(5):293-300. PubMed ID: 19856067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population Pharmacokinetics and Dosing Optimization of Gentamicin in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.
    He S; Cheng Z; Xie F
    Drug Des Devel Ther; 2022; 16():13-22. PubMed ID: 35023902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.